Company
Headquarters: Bala Cynwyd, PA, United States
Employees: 28
CEO: Dr. Carole S. Ben-Maimon
$297.0 Million
USD as of Jan. 1, 2026
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare and progressive genetic disease. Larimar Therapeutics, Inc. is headquartered in Bala Cynwyd, Pennsylvania.
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | $0 |
| EBITDA | $-41,447,000 |
| Gross Profit TTM | $0 |
| Profit Margin | 0.00% |
| Operating Margin | 0.00% |
| Quarterly Revenue Growth | % |
Larimar Therapeutics, Inc. has the following listings and related stock indices.
Stock: NASDAQ: LRMR wb_incandescent